Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Moderna’s SpikeVax vaccine is based on LNP-encapsulated nucleoside-modified mRNA encoding the full-length SARS-Cov-2 spike protein. During the non-clinical phase, the vaccine's immunogenicity ...

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines. This expansion of their 2016 collaboration will ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

There have been renewed efforts to develop cancer vaccines that can modify ... The fusion of mRNA with AI has laid the foundation for ushering in a new era of cancer care. In May 2024, Moderna and ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the ... sparking fears among investors over his anti-vaccine stance. Despite his denial, Kennedy ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other ... the sales trajectory of its respiratory vaccine business. Moderna earlier projected ...

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.